Ernex Therapeutics Files 8-K

Ticker: ERNAW · Form: 8-K · Filed: Dec 11, 2025 · CIK: 748592

Ernexa Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyErnexa Therapeutics Inc. (ERNAW)
Form Type8-K
Filed DateDec 11, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.005
Sentimentneutral

Sentiment: neutral

Topics: disclosure, financial-statements, regulation-fd

TL;DR

Ernex Therapeutics filed an 8-K on 12/11/25, likely for standard disclosures.

AI Summary

On December 11, 2025, Ernexa Therapeutics Inc. filed an 8-K report. The filing primarily serves as a notification of financial statements and exhibits, and a Regulation FD disclosure. No specific material events or financial figures were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates Ernexa Therapeutics Inc. is providing required disclosures to the SEC, which may contain updates on financial statements or other material information.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for disclosures and does not appear to contain any immediately concerning or significant new information.

Key Players & Entities

  • Ernexa Therapeutics Inc. (company) — Registrant
  • December 11, 2025 (date) — Date of earliest event reported
  • 001-11460 (other) — Commission File Number
  • 31-1103425 (other) — IRS Employer Identification No.
  • 1035 Cambridge Street, Suite 18A, Cambridge, MA (address) — Business Address

FAQ

What is the primary purpose of this 8-K filing by Ernexa Therapeutics Inc.?

The filing is a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, serving as a Regulation FD Disclosure and reporting Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported was on December 11, 2025.

What is Ernexa Therapeutics Inc.'s Commission File Number?

Ernex Therapeutics Inc.'s Commission File Number is 001-11460.

What is the business address of Ernexa Therapeutics Inc.?

The business address is 1035 Cambridge Street, Suite 18A, Cambridge, MA.

Has Ernexa Therapeutics Inc. had previous names?

Yes, the company was formerly known as Eterna Therapeutics Inc. (name change 20221017), Brooklyn ImmunoTherapeutics, Inc. (name change 20210325), and NTN BUZZTIME INC (name change 20051230).

Filing Stats: 716 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2025-12-11 08:31:07

Key Financial Figures

  • $0.005 — ch registered Common Stock, par value $0.005 per share ERNA The Nasdaq Stock Mar

Filing Documents

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2025 Ernexa Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-11460 31-1103425 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1035 Cambridge Street , Suite 18A Cambridge , MA 02141 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (617) 798-6700 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol Name of each exchange on which registered Common Stock, par value $0.005 per share ERNA The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934: Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01 Regulation FD Disclosure. On December 11, 2025, Ernexa Therapeutics Inc., a Delaware corporation (the " Company ", " we ", " us ", or " our "), made available a new presentation for investors. A copy of this presentation is attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01. A copy of the presentation is also available on our website at https://investor.ernexatx.com. Without limiting the generality of the foregoing, the "Forward-Looking Statements" disclosure contained in the Investor Presentation is incorporated by reference into this Item 7.01. Use of our Website to Distribute Material Company Information We use our website as a channel of distribution for important Company information. We routinely post on our website important information, including press releases, investor presentations and financial information, which may be accessed by clicking on either the "News" or "Investor Relations" sections of www.ernexatx.com. We may also use our website to expedite public access to time-critical information regarding our Company in advance of or in lieu of distributing a press release or a filing with the Securities and Exchange Commission (the " SEC ") disclosing the same information. Therefore, investors should look to the "News" or "Investor Relations" sections of our website for important and time-critical information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when certain new information is made available on our website. Information contained on, or accessible through, our website is not a part of and is not incorporated by reference in this Current Report on Form 8-K or in any of our other filings with the SEC. The information contained in this Item 7.01, including in Exhibit 99.1 attached hereto, is "furnished" and not "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the " Exchange Act ") or otherwise Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference. Item 9.01 Financial (d) Exhibits. Exhibit Number Description 99.1 Ernexa Therapeutics Investor Presentation – December 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Ernexa Therapeutics Inc. Dated: December 11, 2025 By: /s/ Sanjeev Luther Sanjeev Luther President and Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.